Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations

BACKGROUND: Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (BRAF) mutations. METHODS: A retrospective study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haowei, Cheng, Lei, Zhao, Chao, Zhou, Fei, Jiang, Tao, Guo, Haoyue, Shi, Jinpeng, Chen, Peixin, Tang, Zhuoran, Mao, Shiqi, Jia, Keyi, Ye, Lingyun, Cai, Chenlei, Li, Xuefei, Chen, Xiaoxia, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989805/
https://www.ncbi.nlm.nih.gov/pubmed/36895926
http://dx.doi.org/10.21037/tlcr-22-613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989805/
https://www.ncbi.nlm.nih.gov/pubmed/36895926
http://dx.doi.org/10.21037/tlcr-22-613

Ejemplares similares